Investors Too Gloomy Over Biogen Alzheimer’s Drug
July 23, 2021 at 09:02 AM EDT
There are good reasons to be skeptical that Biogen’s Aduhelm, the first new treatment for Alzheimer’s disease in nearly two decades, will change patients’ lives for the better.
